International Edition

Thursday

May, 26, 2016

Breaking News, World News and Taiwan News.
About Us
Subscribe
Advertise
Contact Us

Roche to buy US biotech company Seragon for as much as US$1.7 bil.

GENEVA--Swiss pharmaceutical group Roche said Wednesday it was buying Seragon Pharmaceuticals, a U.S. biotechnology firm specializing in a new way to fight breast cancer, in a deal worth up to US$1.7 billion (1.2 billion euros).

Seragon, a privately held outfit located in California, is developing a new generation of treatments for the most common form of breast cancer, Roche said in a statement.

Roche said its Genentech subsidiary would be acquiring Seragon, putting US$725 million in cash upfront and adding up to another US$1 billion if "certain predetermined milestones" are met. The deal is expected to be sealed by the end of September if anti-trust regulators raise no objection.

Write a Comment
CAPTCHA Code Image
Type in image code
Change the code
 Receive our promos
 Respond to this email
Subscribe  |   Advertise  |   RSS Feed  |   About Us  |   Career  |   Contact Us
Sitemap  |   Top Stories  |   Taiwan  |   China  |   Business  |   Asia  |   World  |   Sports  |   Life  |   Arts & Leisure  |   Health  |   Editorial  |   Commentary
Travel  |   Movies  |   TV Listings  |   Classifieds  |   Bookstore  |   Getting Around  |   Weather  |   Guide Post  |   Student Post  |   Terms of Use  |   Sitemap
  chinapost search